|Articles|September 22, 2022
New Phesi Analysis of Alzheimer’s Patients Highlights Need for Preventative Approach that Includes Younger Participants
Analysis of 117,000 patients reveals rapid rate of decline in Alzheimer’s patients with 18% loss in cognitive function over a 12-month period.
Advertisement
Phesi identified 117,463 patients who participated in disease modifying trials; representing a significant portion of the patient population. The Phesi analysis reveals the decline that occurs in Alzheimer’s patients over a single 12-month period, with the average 72-year-old suffering from Alzheimer’s losing 18% of cognitive function (measured by MMSE) in 12 months.
Read more about the analysis
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Clinical Trials in 2026: Platformization, AI Fluency, and the Redrawing of the Value Chain
2
Breaking Out of AI Pilot Mode in Clinical Development
3
ACT Brief: Community Sites Compete on Readiness, COA Licensing Bottlenecks Slow Start-Up, and AI’s Foundations in Pharmacovigilance
4
The Challenges of Buying Blind: Why Providing the Clinical Outcome Assessment Measure Prior to License Execution Would Significantly Benefit Clinical Trial Set-Up
5